|
CENPO expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.1757000001621E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.70744999999917E-05 |
| Normal-vs-Stage2 |
8.639500E-04 |
| Normal-vs-Stage3 |
1.0896000000038E-06 |
| Normal-vs-Stage4 |
6.08190000028763E-07 |
| Stage1-vs-Stage2 |
7.622000E-01 |
| Stage1-vs-Stage3 |
1.466810E-01 |
| Stage1-vs-Stage4 |
4.795900E-02 |
| Stage2-vs-Stage3 |
4.958000E-01 |
| Stage2-vs-Stage4 |
1.974380E-01 |
| Stage3-vs-Stage4 |
4.279600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.51590000055479E-07 |
| Normal-vs-AfricanAmerican |
5.458000E-03 |
| Normal-vs-Asian |
5.935200E-03 |
| Caucasian-vs-AfricanAmerican |
9.453200E-01 |
| Caucasian-vs-Asian |
3.178800E-01 |
| AfricanAmerican-vs-Asian |
5.927800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.51710000012773E-07 |
| Normal-vs-Female |
1.44540000002191E-06 |
| Male-vs-Female |
2.037000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.61079999999992E-05 |
| Normal-vs-Age(41-60Yrs) |
1.42709999995105E-06 |
| Normal-vs-Age(61-80Yrs) |
2.03080000038547E-07 |
| Normal-vs-Age(81-100Yrs) |
3.455000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.234800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.672400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.988200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.895800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.561600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.266210E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.415900E-02 |
| Classical-VS-Follicular |
8.124200E-02 |
| Classical-VS-Other |
1.911680E-02 |
| Classical-VS-Normal |
3.50530000000626E-05 |
| Tall-VS-Follicular |
2.711600E-01 |
| Tall-VS-Other |
1.834210E-01 |
| Tall-VS-Normal |
8.54559999985405E-07 |
| Follicular-VS-Other |
1.218240E-01 |
| Follicular-VS-Normal |
1.82619999999911E-05 |
| Other-VS-Normal |
5.974400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.82232000000004E-05 |
| Normal-vs-N1 |
2.34009999999785E-06 |
| N0-vs-N1 |
1.000240E-01 |
|
|
